Dopazo Joaquín, Maya-Miles Douglas, García Federico, Lorusso Nicola, Calleja Miguel Ángel, Pareja María Jesús, López-Miranda José, Rodríguez-Baño Jesús, Padillo Javier, Túnez Isaac, Romero-Gómez Manuel
GT MP Covid-19. SGIDIS, Consejería de Salud y Familias, Junta de Andalucía, Spain.
Área de Bioinformática, Fundación progreso y Salud, Junta de Andalucía, 41013 Sevilla, Spain.
J Pers Med. 2021 May 26;11(6):475. doi: 10.3390/jpm11060475.
The COVID-19 pandemic represents an unprecedented opportunity to exploit the advantages of personalized medicine for the prevention, diagnosis, treatment, surveillance and management of a new challenge in public health. COVID-19 infection is highly variable, ranging from asymptomatic infections to severe, life-threatening manifestations. Personalized medicine can play a key role in elucidating individual susceptibility to the infection as well as inter-individual variability in clinical course, prognosis and response to treatment. Integrating personalized medicine into clinical practice can also transform health care by enabling the design of preventive and therapeutic strategies tailored to individual profiles, improving the detection of outbreaks or defining transmission patterns at an increasingly local level. SARS-CoV2 genome sequencing, together with the assessment of specific patient genetic variants, will support clinical decision-makers and ultimately better ways to fight this disease. Additionally, it would facilitate a better stratification and selection of patients for clinical trials, thus increasing the likelihood of obtaining positive results. Lastly, defining a national strategy to implement in clinical practice all available tools of personalized medicine in COVID-19 could be challenging but linked to a positive transformation of the health care system. In this review, we provide an update of the achievements, promises, and challenges of personalized medicine in the fight against COVID-19 from susceptibility to natural history and response to therapy, as well as from surveillance to control measures and vaccination. We also discuss strategies to facilitate the adoption of this new paradigm for medical and public health measures during and after the pandemic in health care systems.
新冠疫情为利用精准医学的优势来预防、诊断、治疗、监测和管理这一公共卫生新挑战提供了前所未有的机遇。新冠病毒感染情况高度多变,从无症状感染到严重的、危及生命的表现都有。精准医学在阐明个体对感染的易感性以及临床病程、预后和治疗反应的个体间差异方面可发挥关键作用。将精准医学融入临床实践还可通过设计针对个体特征的预防和治疗策略来改变医疗保健,在地方层面更好地检测疫情爆发或确定传播模式。新冠病毒基因组测序以及对特定患者基因变异的评估,将为临床决策者提供支持,并最终找到抗击这种疾病的更好方法。此外,它将有助于更好地对患者进行分层和选择以开展临床试验,从而增加获得阳性结果的可能性。最后,制定一项在临床实践中实施新冠疫情精准医学所有可用工具的国家战略可能具有挑战性,但与医疗保健系统的积极变革相关联。在本综述中,我们从易感性到自然史、从治疗反应以及从监测到控制措施和疫苗接种等方面,对精准医学在抗击新冠疫情中的成就、前景和挑战进行了更新。我们还讨论了在疫情期间及之后促进医疗保健系统采用这种新范式用于医疗和公共卫生措施的策略。